CTLA4 and Sepsis: Cardiac-specific biomarkers previously validated in sepsis research now inform novel targeting strategies, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibition.